AM
adil mardinoglu
Centre for Host–Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London
United Kingdom
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- FDA-approved Drug Repositioning for P-glycoprotein Overexpressing Resistant Cancer
FDA-approved Drug Repositioning for P-glycoprotein Overexpressing Resistant Cancer
16k
Total downloads
102k
Total views and downloads
33 Authors
- AS
anna seelig
Biozentrum, University of Basel
Switzerland
- BK
benedikt kortüm
Experimental and Clinical Research Center, Charité University Medicine and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association
Germany
- BT
beste turanli
Department of Bioengineering, Istanbul Medeniyet University
Türkiye
- CJ
chunxue jiang
School of Pharmacy, Sungkyunkwan University
Republic of Korea
- DK
dennis kobelt
Experimental and Clinical Research Center, Charité University Medicine and the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association
Germany
- GT
gerard tromp
Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University
South Africa
- GG
gizem gulfidan
Department of Bioengineering, Marmara University
Türkiye
- HB
hande beklen
Department of Bioengineering, Marmara University
Türkiye
- HK
helena kuivaniemi
Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University
South Africa
- HS
hyung sik kim
School of Pharmacy, Sungkyunkwan University
Republic of Korea
- JY
ji young kim
School of Pharmacy, Sungkyunkwan University
Republic of Korea
Published in
Frontiers in Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore